论文部分内容阅读
将171只体质量200~250g 7周龄雄性SD大鼠随机分为正常对照组(Ⅰ组,25只)和Ⅱ型糖尿病模型组(Ⅱ组,146只),采用高脂高糖饲料喂养结合STZ腹腔注射的方法建立Ⅱ型糖尿病大鼠动物模型,定期对大鼠体质量、空腹血糖、糖耐量、血清胰岛素及胰腺组织等指标进行检测。结果显示:第42天,与正常对照组相比,模型组大鼠体质量显著升高(P<0.05),血糖无明显差异(P>0.05),糖耐量曲线下面积增大(P<0.05),胰腺外分泌腺内大量脂肪异位沉积;第56天,与正常对照组相比,模型组体质量显著降低(P<0.05),血糖、血清胰岛素、胰岛素抵抗指数显著升高(P<0.05),糖耐量曲线下面积显著增大(P<0.05),胰岛素敏感指数显著降低(P<0.05),胰岛减小、减少,胰岛形状不规整,部分胰岛细胞内脂质沉积;模型组成模率70%、死亡率5%、淘汰率25%。结果表明:对SD大鼠采用高脂高糖配方饲料结合低剂量链脲佐菌素腹腔注射可成功制备Ⅱ型糖尿病大鼠动物模型,并具有Ⅱ型糖尿病基本特征胰岛素抵抗及胰岛β细胞轻度损伤同时出现的临床特点,是研究Ⅱ型糖尿病及其新药开发的理想动物模型。
A total of 171 male SD rats aged 200-250 g were randomly divided into normal control group (group Ⅰ, n = 25) and type Ⅱ diabetic group (n = 146). The rats were fed with high fat and high glucose diet STZ intraperitoneal injection method to establish animal model of type 2 diabetic rats, regularly measuring body weight, fasting blood glucose, glucose tolerance, serum insulin and pancreatic tissue and other indicators. The results showed that on the 42nd day, compared with the normal control group, the body weight of the model group was significantly increased (P <0.05), the blood glucose had no significant difference (P> 0.05), and the area under the glucose tolerance curve increased (P <0.05 (P <0.05). The blood glucose, serum insulin and insulin resistance index increased significantly on the 56th day (P <0.05) compared with the normal control group ), The area under the curve of glucose tolerance increased significantly (P <0.05), the insulin sensitivity index decreased significantly (P <0.05), the islets decreased and decreased, the shape of islets became irregular and lipid deposition in some islet cells. 70%, 5% mortality rate, the elimination rate of 25%. The results showed that the animal model of type 2 diabetic rats could be successfully prepared by intraperitoneal injection of low-dose streptozotocin (STZ) and high-fat and high-sucrose diet in SD rats, with the basic features of type II diabetes insulin resistance and islet β-cell mild The clinical characteristics of the concurrent injury are ideal animal models for studying the development of type 2 diabetes and its new drugs.